Without question, some of BioInformant’s most popular content has been our exclusive interviews with stem cell executives and key opinion leaders (KOL). Highlighted below are six of our most popular interviews. Enjoy! [Read more…]
Imagine Increasing Revenue from Stem Cell Products and Decreasing Risk
We have helped hundreds of the top companies increase revenue from stem cell products and decrease risk. The key is targeted market intelligence, because it will help you to approach institutional investors for fundraising rounds, guide internal decision-making within your company, and reduce the risk that has traditionally accompanied new product development. Simply put, it will help you make smarter decisions, faster.
Whether or not you can invest in the recently released global strategic report, “Stem Cell Research Products – Opportunities, Tools, and Technologies,” the following is an important introduction to the stem cell research products marketplace, including key trends and future projections. [Read more…]
Top 5 Stem Cell Interviews of 2015
As 2016 approaches, it is an important time to look back on 2015 and all that the year entailed for stem cell advances. During 2016, I was honored to have interviewed a number of key thought leaders in the stem cell space, including the CEO of the largest dental stem cell company in the world (Tony Veverka of BioEden), Chief Business Officer for a company creating the world’s largest blood cell repository for iPSC production (James Lovgren of ORIG3N), and VP of Research and Development for one of the most innovative companies operating within the stem cell sector (Dr. Grynspan of Stem Cell Medicine).
Throughout 2015, my team and I conducted dozens of other interviews as well, with stem cell executives, investors, and researchers. These interviews were published on our stem cell industry blog and also informed market projections for BioInformant’s stem cell and cord blood market intelligence reports. [Read more…]